$KROS

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%

The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 26, 2025, 2:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 27, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% — source image
Decision brief

The 30-second read

$KROSBullishMed
01

Why it matters

While the target suggests significant upside, actual stock movement depends on broader market conditions and company-specific developments.

02

Market read

The news is relevant for biotech investors and traders focusing on small-cap growth stocks with upcoming earnings revisions.

03

What to watch

Potential regulatory hurdles, clinical trial outcomes, or macroeconomic factors could negate the upside potential.

Timing: Immediate, given the recent publication date and ongoing earnings revisions.

Background

Keros Therapeutics (KROS) has received analyst target upgrades, indicating anticipated growth.

Company-level read

Ticker impact

$KROSBullishMedium confidence
Context

High relevance due to recent analyst target and earnings revision trends.

Expected impact

Moderate upward movement in the near term, approximately 10-15%, contingent on continued earnings revision trends.

Evidence & confidence

The upward trend in earnings estimates indicates investor optimism, but the low relevance score (0.2842) and the modest sentiment (bullish at 38.66%) suggest caution. External factors and market conditions could influence actual performance.

Market effects

Potential positive impact on biotech and life sciences sectors, possibly boosting related stocks.

Limited to North American markets, where KROS is primarily traded.

Minimal, as the news pertains to a specific biotech company with niche relevance.

Counterpoint

Earnings estimate revisions may be overly optimistic; empirical research suggests limited effectiveness of such metrics in predicting stock performance.

Key entities

  • Keros Therapeutics

    Biotech firm focusing on therapies for hematology and oncology.

  • Wall Street Analysts

    Financial analysts providing target price estimates and revisions.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.